Scarica l'app Stockscreener
27.21
6.79%
1.73
Dopo l'orario di chiusura:
27.39
0.18
+0.66%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$25.48
Aprire:
$25.97
Volume 24 ore:
149.70M
Relative Volume:
3.25
Capitalizzazione di mercato:
$154.70B
Reddito:
$63.83B
Utile/perdita netta:
$10.77B
Rapporto P/E:
14.47
EPS:
1.88
Flusso di cassa netto:
$12.44B
1 W Prestazione:
+12.95%
1M Prestazione:
+9.89%
6M Prestazione:
+10.88%
1 anno Prestazione:
-5.09%
Intervallo 1D:
$25.58
$27.45
Intervallo di 1 settimana:
$23.58
$27.45
Portata 52W:
$20.91
$30.43
Pfizer Inc Stock (PFE) Company Profile
Nome
Pfizer Inc
Settore
Industria
Telefono
(212) 733-2323
Indirizzo
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Confronta PFE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
27.21 | 144.87B | 63.83B | 10.77B | 12.44B | 1.88 |
|
LLY
Lilly Eli Co
|
825.42 | 684.00B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
186.05 | 446.55B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
244.38 | 409.03B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
131.72 | 248.25B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
90.13 | 209.64B | 63.43B | 16.42B | 14.72B | 6.49 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-25 | Ripresa | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Downgrade | Argus | Buy → Hold |
| 2024-02-23 | Iniziato | Guggenheim | Buy |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-10-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-17 | Reiterato | JP Morgan | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-06-29 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Downgrade | UBS | Buy → Neutral |
| 2023-01-17 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-20 | Reiterato | Cowen | Outperform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-13 | Aggiornamento | UBS | Neutral → Buy |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-12-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Ripresa | Goldman | Neutral |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-10-12 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-16 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-27 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-07-30 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Ripresa | Morgan Stanley | Overweight |
| 2019-02-20 | Ripresa | Citigroup | Neutral |
| 2019-01-31 | Aggiornamento | Argus | Hold → Buy |
| 2019-01-31 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Downgrade | UBS | Buy → Neutral |
| 2018-12-11 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Mostra tutto
Pfizer Inc Borsa (PFE) Ultime notizie
Pfizer (PFE) Soars on Tariff Exemption, Landmark US Govt Deal - MSN
Pfizer Stock, Other Drugmakers Rally Again - The Wall Street Journal
Why Pfizer Stock Trounced the Market Today - AOL.com
Pfizer (PFE) Shares Surge on Analyst Upgrade and Government Deal - GuruFocus
Pfizer (PFE) Influences U.S. Drug Pricing Strategy - GuruFocus
Pfizer stock maintains Outperform rating at BMO after Trump deal - Investing.com
Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs - HIT Consultant
Will more drugmakers agree to deals with the White House after Pfizer? - KVAL
Trump-Pfizer Deal Pushes Health Care Stocks To Best Rally In 5 Years - inkl
Pfizer (PFE) Stock Rises Amid Positive Developments and Strategi - GuruFocus
Why Is Pfizer (PFE) Stock Soaring Today - FinancialContent
Pfizer Shares Are Trading Higher Wednesday: What's Going On? - Benzinga
Pfizer to lower some U.S. drug prices; 'TrumpRx' platform to come - Chain Store Age
Pfizer (PFE) Rallies on Drug Pricing Agreement with U.S. - GuruFocus
Lithium Americas, Reddit, Nike, Plug Power, Pfizer: Stocks Making The Biggest Moves Today - MSN
U.S. Pfizer deal sends health stocks sharply higher as drugmakers court Trump - The Globe and Mail
Pfizer (PFE): A Healthcare Giant Offering Steady Dividend Income - MSN
Pfizer Inc. Stock (PFE) Opinions on U.S. Drug Pricing Deal - Quiver Quantitative
Why Shares in Novo Nordisk Bumped Higher Today - The Motley Fool
Eli Lilly, Amgen among gainers as Pfizer – U.S. drug pricing deal sparks “relief rally” - Seeking Alpha
Pfizer Stock Climbs To Multi-Month High On Trump Drug Pricing Breakthrough - Yahoo Finance
Will Pfizer Head Higher?Pfizer (NYSE:PFE) - Benzinga
Pfizer, Trump agree to lower drug prices - Taipei Times
Pfizer Just Announced a Massive Deal with TrumpRx. Here's What Investors Need to Know - Yahoo Finance
Pfizer to lower some drug prices as White House builds "TrumpRx" website - CBS News
Headlines Boost Pharma Stocks. What the Charts of Pfizer, Johnson & Johnson, Jazz Pharmaceuticals Say - Barron's
Pfizer's TrumpRx Pact Sends Shockwaves: Why UnitedHealth, Lilly And CVS Can't Look Away - Benzinga
Pfizer Strikes Deal With Trump to Lower Medicaid Drug Costs - U.S. News & World Report
Trump announces ‘TrumpRx’ site for discounted drugs and deal with Pfizer to lower prices - news8000.com
Analyst recommendations: Pfizer, Tesla, Nike, Amazon, Walt Disney… - MarketScreener
US Pfizer deal powers European health stocks as Trump policy haze clears - Yahoo Finance
Pfizer Strikes Deal with Trump to Lower Medicaid Drug Costs - Lebanon Democrat
Acute Social Anxiety Disorder Market on Track for Major Expansion by 2034, According to DelveInsight | GlaxoSmithKline Plc, Viatris Inc, Johnson & Johnson, Novartis AG, Pfizer Inc, AstraZeneca Plc - Barchart.com
Mark Cuban gives Trump props over Pfizer deal to lower drug costs | RISING - The Hill
S&P 500 Rises 0.41% as Pfizer Soars 6.83% Amid Mixed Market Signals - Markets Mojo
Pfizer stock holds steady as TD Cowen reiterates $30 price target - Investing.com
SHASQI STRENGTHENS BOARD OF DIRECTORS WITH THE APPOINTMENT OF FORMER CHIEF DEVELOPMENT OFFICER AT PFIZER ONCOLOGY - PR Newswire
Pfizer (PFE) Drug Pricing Deal with U.S. Government Raises Quest - GuruFocus
ABSSSI Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Glenmark Pharma, Melinta Therapeutics, Sandoz Inc, Paratek Pharma, AbbVie Inc., Allergan PLC, Merck & Co. Inc., Pfizer - The Globe and Mail
Is Pfizer Stock A Buy At $25? - Trefis
Pfizer (PFE) Granted Tariff Relief in New U.S. Drug Pricing Deal - GuruFocus
Pfizer reaches agreement with the Trump administration - MarketScreener
Pfizer (PFE) Teams Up with C4 Therapeutics for Clinical Trial Co - GuruFocus
European healthcare stocks surge after US deal with Pfizer - Yahoo Finance
C4 Therapeutics, Inc. Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma - MarketScreener
Swiss pharma companies likely to follow Pfizer-US price deal, business lobby says - Reuters
AstraZeneca, Sanofi Surge on Optimism Pharma Can Clinch US Price Deals - Bloomberg.com
Pfizer – U.S. drug pricing deal boosts EU drugmakers (AZN:NASDAQ) - Seeking Alpha
Pfizer: First Out of the Gate With a Drug Pricing Agreement; Positioned to Avoid Major Headwind - Morningstar Canada
What happens now that the government has shut down. And, a pricing deal with Pfizer - NPR
C4 Therapeutics Partners with Pfizer for Phase 1b Clinical Trial of Cemsidomide in Combination with Elranatamab for Multiple Myeloma Treatment - Quiver Quantitative
Pfizer Inc Azioni (PFE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.78%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):